NCT02437370View on ClinicalTrials.gov

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 1, 2015

Primary Completion Date

August 7, 2019

Study Completion Date

March 10, 2020

Conditions
Metastatic Urothelial Carcinoma of the Renal Pelvis and UreterRecurrent Bladder CarcinomaRecurrent Urothelial Carcinoma of the Renal Pelvis and UreterRegional Urothelial Carcinoma of the Renal Pelvis and UreterStage III Bladder Urothelial CarcinomaStage III Urethral CancerStage IV Bladder Urothelial CarcinomaStage IV Urethral CancerUrethral Urothelial Carcinoma
Interventions
DRUG

Pembrolizumab

Given IV

DRUG

Docetaxel

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, Davis

OTHER

NCT02437370 - Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer | Biotech Hunter | Biotech Hunter